Lilly reports positive interim results from Heart-2 trial of VERVE-102
The study involved 35 participants with heterozygous familial hypercholesterolaemia or premature coronary artery disease.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance